KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q3 2025 value amounting to $4.4 million.

  • CRISPR Therapeutics AG's Depreciation and Depletion fell 833.33% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year decrease of 414.51%. This contributed to the annual value of $19.2 million for FY2024, which is 303.03% down from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Depreciation and Depletion stood at $4.4 million, which was down 833.33% from $4.6 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Depreciation and Depletion peaked at $7.3 million during Q2 2022, and registered a low of $2.7 million during Q1 2021.
  • In the last 5 years, CRISPR Therapeutics AG's Depreciation and Depletion had a median value of $4.9 million in 2023 and averaged $5.0 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first skyrocketed by 14800.0% in 2021, then crashed by 3150.68% in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Depreciation and Depletion (Quarter) stood at $6.2 million in 2021, then fell by 6.45% to $5.8 million in 2022, then decreased by 15.52% to $4.9 million in 2023, then fell by 2.04% to $4.8 million in 2024, then fell by 8.33% to $4.4 million in 2025.
  • Its Depreciation and Depletion stands at $4.4 million for Q3 2025, versus $4.6 million for Q2 2025 and $4.7 million for Q1 2025.